• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Cubist Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011 Product Image

Cubist Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011

  • Published: November 2011
  • 103 pages
  • Global Markets Direct

Cubist Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Cubist Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011” provides data on the Cubist Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Cubist Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Cubist Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Cubist Pharmaceuticals, Inc. - Brief Cubist Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Cubist Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- READ MORE >



List of Tables
List of Figures
Cubist Pharmaceuticals, Inc. Snapshot
Cubist Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Cubist Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Cubist Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Cubist Pharmaceuticals, Inc. – Pipeline Products Glance
Cubist Pharmaceuticals, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Cubist Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Cubist Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Cubist Pharmaceuticals, Inc. – Drug Profiles
CB-183,315
Product Description
Mechanism of Action
R&D Progress
CB-183,872
Product Description
Mechanism of Action
R&D Progress
CXA-101
Product Description
Mechanism of Action
R&D Progress
CXA-101 + Tazobactam
Product Description
Mechanism of Action
R&D Progress
Cubist Pharmaceuticals, Inc. – Pipeline Analysis
Cubist Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Cubist Pharmaceuticals, Inc. - Pipeline Products By Target
Cubist Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Cubist Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Cubist Pharmaceuticals, Inc. – Recent Pipeline Updates
Cubist Pharmaceuticals, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
CB-182,804
HepeX-B
Cubist Pharmaceuticals, Inc. – Company Statement
Cubist Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Sep 30, 2003: Cubist Pharmaceuticals Announces Completion of Independent Data Monitoring Committee Review of Initial Endocarditis/Bacteremia Data for Cubicin
Jun 30, 2010: Cubist Initiates Phase II Study Of CXA-201 For Complicated Intra-Abdominal Infections
Sep 29, 2011: Cubist Pharmaceuticals To Move CDAD Candidate CB-183,315 Into Phase III Trial For Treatment Of Diarrhea
Jun 29, 2010: Cubist Announces All Objectives Met In Phase II CXA-101 Complicated Urinary Tract Infections Study
Jun 27, 2005: CUBICIN Meets Primary Endpoints in Ground-Breaking Staphylococcus Aureus Endocarditis/Bacteremia Study; Cubist Plans to File sNDA for Expanded Label Before Year-end
Mar 27, 2009: Cubist Pharmaceuticals Initiates Phase 2 Trial for Therapy to Reduce Blood Loss During Surgery
Oct 26, 2004: Cubist Pharmaceuticals Announces Completion of the Fourth Safety Review of Endocarditis/Bacteremia Data for Cubicin by Data Monitoring Committee
Sep 26, 2005: Cubist Pharmaceuticals Files sNDA to Expand CUBICIN Label for Staphylococcus Aureus Bacteremia With Known or Suspected Endocarditis; Company Requests Priority Review
Sep 25, 2007: IV Antibiotic CUBICIN Approved for Marketing in Canada
Jul 25, 2007: Positive Opinion for Expanded Label of CUBICIN Received from European Regulatory Authority; Decision Expected This September
May 25, 2006: FDA Approves Expanded Label for IV Antibiotic CUBICIN to Add Bloodstream Infections Including Right-Sided Infective Endocarditis Caused by MSSA and MRSA
Mar 24, 2009: Calixa Therapeutics Announces Positive Phase I Results For CXA-101, A Novel Intravenous Cephalosporin Antibiotic With Excellent Anti-Pseudomonal Activity
Mar 24, 2006: FDA Issues Approvable Letter for CUBICIN sNDA
Nov 23, 2004: Cubist Pharmaceuticals And XTL Biopharmaceuticals Announces Completion Of Independent Data And Safety Monitoring Board (DSMB) Review Of Phase 2 Data For HepeX-B
Feb 23, 2005: Cubist Pharmaceuticals Announces Approval of Second Bulk Drug Manufacturing Facility; Plant will Provide Additional Production of Cubicin
Jan 23, 2006: CUBICIN Granted Marketing Approval in Europe
Dec 22, 2005: Cubist Pharmaceuticals Reports Results From Phase 2 Study HepeX-B, Which Was Licensed From XTLBio
Mar 22, 2007: Cubist Pharmaceuticals Licenses Rights for Development and Commercialization of CUBICIN in Japan to Merck & Co., Inc.
Feb 22, 2005: Cubist Pharmaceuticals Announces Completion of Treatment Phase for All Patients in the Cubicin Endocarditis/Bacteremia Study; DMC Completes the Fifth Safety Review
Nov 21, 2005: FDA Accepts CUBICIN sNDA and Grants Priority Review
Oct 21, 2008: CUBICIN Outcomes Registry and Experience (CORE) Marks Milestone
Apr 20, 2005: Cubist Pharmaceuticals Reports First Quarter 2005 Results; Reiterates 2005 Annual CUBICIN Revenue Guidance of $110-120 Million
Jul 19, 2006: XTL Provides Update On HepeX-B Program
Feb 17, 2009: Phase I Trial Begins For Investigational New Drug For MDR Gram-Negative Infections
Dec 16, 2005: Pivotal Phase 3 Cubicin Data Presented at ICAAC Late Breaker Session; Landmark Study Finds CUBICIN Comparable to Dual Therapy Standard of Care for the Treatment of Staph Infections of the Bloodstream and Heart
Oct 16, 2008: Cubist Pharmaceuticals Q3 2008 Revenues up 41%; Net Income up 39%: Total Revenues $112.4 Million; CUBICIN Net Product Revenues $110.6 Million
Oct 16, 2008: Cubist Pharmaceuticals Q3 2008 Revenues up 41%; Net Income up 39%: Total Revenues $112.4 Million; CUBICIN Net Product Revenues $110.6 Million
Aug 16, 2006: The New England Journal of Medicine Publishes Results of Cubist's Landmark Study of Staphylococcus Aureus Blood Stream Infections; Study Results Led to Recent Label Expansion for CUBICIN
Jun 16, 2011: Cubist Announces Positive Results From Phase II Trial Of CB-183,315 For CDAD Program
Jun 16, 2011: Cubist Announces Positive Results From Phase II Trial Of CXA-201
Sep 15, 2009: Calixa Therapeutics To Make Multiple Presentations On CXA-101 And CXA-101/Tazobactam At The 49th Annual Interscience Conference On Antimicrobial Agents And Chemotherapy
Dec 14, 2009: Cubist Pharmaceuticals To Acquire Calixa Therapeutics
Jul 13, 2010: Cubist Announces Objectives Met in Phase 2 Safety Study of CUBICIN in Prosthetic Joint Infections
Feb 13, 2009: Cubist Pharmaceuticals Announces Start Of First-in-Human Clinical Trial For Investigational New Drug For Clostridium difficile Infections
Sep 12, 2007: Cubist Pharmaceuticals to Seek Technical Correction in One of Its U.S. CUBICIN Patents
Sep 12, 2003: FDA Approves Cubicin, Previously Cidecin, an Antibiotic Developed by Cubist Pharmaceuticals
May 12, 2010: Markman Hearing in CUBICIN Patent Litigation Rescheduled to June 9, 2010
Dec 11, 2009: Trial Date Set for CUBICIN Patent Litigation
Nov 09, 2004: Cubist Pharmaceuticals Announces the Completion of Patient Enrollment in Cubicin's Phase 3 Endocarditis/Bacteremia Trial
Sep 09, 2005: CUBICIN Phase 3 Endocarditis/Bacteremia Trial Abstract Accepted for ICAAC
Aug 09, 2005: XTLbio Announces The End Of Patient Dosing In HepeX-B Hepatitis B Phase 2 Trial
Dec 08, 2005: Cubist Pharmaceuticals Releases Data from Late Breaker Abstract: Results of CUBICIN Phase 3 S. Aureus Bacteremia/Endocarditis Trial; ICAAC Pre-Conference Abstract Program Includes 35 CUBICIN-Related Abstracts
Apr 08, 2010: Cubist Enrolls First Subject In Phase II Trial For Therapy To Treat Clostridium Difficile-Associated Diarrhea
Sep 06, 2007: Cubist Pharmaceuticals' CUBICIN Approved for Additional Indications in the EU
Mar 06, 2006: Cubist Pharmaceuticals Reports Positive Outcome from FDA Anti-Infective Drugs Advisory Committee; PDUFA Date for FDA Review of CUBICIN sNDA is March 24th
Mar 06, 2006: Cubist Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee Meeting to Discuss CUBICIN sNDA
Jan 05, 2009: Cubist Pharmaceuticals Announces Submission Of 2 INDs Targeting Serious Infections Caused By MDR Gram-Negative Pathogens And By Clostridium Difficile
Jan 05, 2009: Cubist Pharmaceuticals Announces Submission Of 2 INDs Targeting Serious Infections Caused By MDR Gram-Negative Pathogens And By Clostridium Difficile
Jan 05, 2009: Cubist Pharmaceuticals, the Developer of CUBICIN, Announces Submission of 2 INDs Targeting Serious Infections Caused by MDR Gram-negative Pathogens and by Clostridium difficile
Dec 04, 2006: Cubist Pharmaceuticals Licenses Rights for Development and Commercialization of CUBICIN in China to AstraZeneca
Nov 04, 2003: Cubist Pharmaceuticals Begins Shipping Cubicin to U.S. Institutions
Aug 04, 2003: XTLbio’s HepeX-B Receives Orphan Drug Designation From The FDA
Oct 03, 2003: Cubist Pharmaceuticals and Chiron Corporation Announce CUBICIN International Commercialization Agreement
Mar 03, 2006: Cubist Pharmaceuticals Announces Posting of Briefing Documents for FDA Anti-Infective Drugs Advisory Committee (AIDAC) Meeting; AIDAC Meeting to Review CUBICIN sNDA is Monday, March 6th
Mar 03, 2005: Cubist Pharmaceuticals to Purchase 2% Reduction in CUBICIN Royalty Rate from Lilly with Common Stock
Dec 02, 2004: Chiron and Cubist Pharmaceuticals Announce the Filing for EU Regulatory Approval to Market Cubicin -Daptomycin for Injection-
Dec 01, 2010: Cubist Receives FDA Approval For Two-Minute IV Injection Of CUBICIN
Aug 01, 2011: Cubist Announces First Patient Dosed In Pivotal Global Phase III Trial Of CXA-201 For Complicated Urinary Tract Infections
Aug 01, 2007: CUBICIN Approved for S. aureus Bloodstream Infections in South Korea and Taiwan
Jul 01, 2011: Merck Receives Approval To Market CUBICIN In Japan
Jul 01, 2009: Calixa Therapeutics Announces Initiation Of Phase 2 Clinical Trial Of Its Antibiotic, CXA-101, In Patients With Complicated Urinary Tract Infections
Financial Deals Landscape
Cubist Pharmaceuticals, Inc., Deals Summary
Cubist Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Cubist Pharmaceuticals Acquires 2% Royalty Stream Of CUBICIN From Eli Lilly
Venture Financing
FORMA Therapeutics Secures Additional $3 Million In Series B Financing Round
Calixa Therapeutics Secures $30 Million In Series A Financing
Illumigen Biosciences Secures $12 Million In Venture Financing
Illumigen Biosciences Secures $5 Million In Series B Financing
Partnerships
Optimer Pharmaceuticals Enters Into Co-Promotion Agreement With Cubist Pharmaceuticals
Evotec Extends Research Agreement With Cubist Pharmaceuticals
Cubist Pharmaceuticals Enters Into Co-Development Agreement With Hydra Biosciences
Evotec Enters Into Research Agreement With Cubist Pharmaceuticals
Beactica Enters Into Co-Development Agreement With Cubist Pharmaceuticals
FORMA Therapeutics Enters Into Co-Development Agreement With Cubist Pharmaceuticals
Cubist Pharmaceuticals Enters Into Co-Development Agreement With Alnylam
Cubist Pharmaceuticals Enters Into Co-Promotion Agreement With AstraZeneca
deCODE biostructures Enters Into Research Agreement With Cubist Pharmaceuticals
Cubist Pharmaceuticals Enters Into Co-Marketing Agreement With Kuhnil Pharmaceuticals
Licensing Agreements
Cubist Pharmaceuticals Enters Into Licensing Agreement With Dyax
Cubist Pharmaceuticals Enters Into Licensing Agreement With Merck
AstraZeneca Enters Into Licensing Agreement With Cubist Pharmaceuticals
Cubist Pharmaceuticals Enters Into Licensing Agreement With XTL Biopharmaceuticals
Equity Offering
Cubist Pharmaceuticals Completes Public Offering Of $120 Million
Debt Offering
Cubist Pharmaceuticals Completes Private Placement Of Convertible Senior Notes Due 2017 For $450 Million
Cubist Pharmaceuticals Completes Public Offering Of 2.25% Convertible Notes For $350 Million
Acquisition
Cubist Pharmaceuticals Commences Tender Offer To Acquire Adolor For $415 Million
Cubist Pharmaceuticals Acquires Calixa Therapeutics
Cubist Pharmaceuticals Acquires Illumigen Biosciences
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Cubist Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Cubist Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011
Cubist Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, H2 2011
Cubist Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, H2 2011
Cubist Pharmaceuticals, Inc. – Phase III, H2 2011
Cubist Pharmaceuticals, Inc. - Phase II, H2 2011
Cubist Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, H2 2011
Cubist Pharmaceuticals, Inc. - Pipeline By Target, H2 2011
Cubist Pharmaceuticals, Inc. – Pipeline By Route of Administration, H2 2011
Cubist Pharmaceuticals, Inc. – Pipeline By Molecule Type, H2 2011
Cubist Pharmaceuticals, Inc. – Recent Pipeline Updates, H2 2011
Cubist Pharmaceuticals, Inc. - Discontinued Pipeline Products, H2 2011
Cubist Pharmaceuticals, Inc., Subsidiaries, H2 2011
Cubist Pharmaceuticals, Inc., Deals Summary, H2 2011
Cubist Pharmaceuticals Acquires 2% Royalty Stream Of CUBICIN From Eli Lilly
FORMA Therapeutics Secures Additional $3 Million In Series B Financing Round
Calixa Therapeutics Secures $30 Million In Series A Financing
Illumigen Biosciences Secures $12 Million In Venture Financing
Illumigen Biosciences Secures $5 Million In Series B Financing
Optimer Pharmaceuticals Enters Into Co-Promotion Agreement With Cubist Pharmaceuticals
Evotec Extends Research Agreement With Cubist Pharmaceuticals
Cubist Pharmaceuticals Enters Into Co-Development Agreement With Hydra Biosciences
Evotec Enters Into Research Agreement With Cubist Pharmaceuticals
Beactica Enters Into Co-Development Agreement With Cubist Pharmaceuticals
FORMA Therapeutics Enters Into Co-Development Agreement With Cubist Pharmaceuticals
Cubist Pharmaceuticals Enters Into Co-Development Agreement With Alnylam
Cubist Pharmaceuticals Enters Into Co-Promotion Agreement With AstraZeneca
deCODE biostructures Enters Into Research Agreement With Cubist Pharmaceuticals
Cubist Pharmaceuticals Enters Into Co-Marketing Agreement With Kuhnil Pharmaceuticals
Cubist Pharmaceuticals Enters Into Licensing Agreement With Dyax
Cubist Pharmaceuticals Enters Into Licensing Agreement With Merck
AstraZeneca Enters Into Licensing Agreement With Cubist Pharmaceuticals
Cubist Pharmaceuticals Enters Into Licensing Agreement With XTL Biopharmaceuticals
Cubist Pharmaceuticals Completes Public Offering Of $120 Million
Cubist Pharmaceuticals Completes Private Placement Of Convertible Senior Notes Due 2017 For $450 Million
Cubist Pharmaceuticals Completes Public Offering Of 2.25% Convertible Notes For $350 Million
Cubist Pharmaceuticals Commences Tender Offer To Acquire Adolor For $415 Million
Cubist Pharmaceuticals Acquires Calixa Therapeutics
Cubist Pharmaceuticals Acquires Illumigen Biosciences

List of Figures
Cubist Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Cubist Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011
Cubist Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, H2 2011
Cubist Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, H2 2011
Cubist Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, H2 2011
Cubist Pharmaceuticals, Inc. - Pipeline By Target, H2 2011
Cubist Pharmaceuticals, Inc. – Pipeline By Route of Administration, H2 2011
Cubist Pharmaceuticals, Inc. – Pipeline By Molecule Type, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos